Abstract: New substituted 2,2-dimethyl-.omega.-phenoxyalkanoic acids and esters of formula: ##STR1## wherein: X, A, B, R, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7 and Z are as defined in the specification,The corresponding enantiomers and diastereoisomers, and the physiologically tolerable salts thereof with appropriate bases.The products of the invention may be used therapeutically.

Abstract: The invention provides new compounds pertaining to the class of:aryl methoxy phenyl alkyl heterocyclic spiro compounds, enantiomers, diastereoisomers and physiologically-tolerable salts thereof.For example:8-{2-?3-quinol-2-yl methoxy)phenyl!ethyl}-3,8-diaza-1-oxa-2-oxo spiro?4,5!decane is described.Medicinal products containing the same are useful in the treatment of any pathology involving modifications of leukotriene metabolism.

Abstract: New substituted phenoxyisobutyric acids and esters that can be used as medicaments and correspond to the formula: ##STR1## wherein X, A, R, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7 and Z are as defined in the description.Those compounds and their physiologically tolerable salts can be used therapeutically.

Abstract: New substituted phenoxyisobutyric acids and esters that can be used as medicaments and correspond to the formula: ##STR1## wherein X, A, R, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7 and Z are as defined in the description.Those compounds and their physiologically tolerable salts can be used therapeutically.

Abstract: Novel bicyclic pyrimidine compounds for use as drugs and having formula (I). Said novel compounds and physiologically tolerable salts thereof may be used in therapeutics, particularly for suppressing tumour cell resistance to antineoplastic agents.

Abstract: The compounds are 5-(4-substituted benzyl)thiazolidine-2,4-diones, enantiomers, diastereoisomers and pharmaceutically tolerable salts thereof, useful for treating conditions of insulin-resistance and/or non insulin-dependent diabetes.A compound disclosed is: .(R,S)-5-{4-[2-benzofuran-2-yl)carbonylamino)ethyl]benzyl}thiazolidine-2,4 -dione.

Abstract: The compounds are 5-(4-substituted benzyl)thiazolidine-2,4-diones, enantiomers, diastereoisomers and pharmaceutically tolerable salts thereof, useful for treating conditions of insulin-resistance and/or non insulin-dependent diabetes.A compound disclosed is: 5-{4-[2-(2-methoxy-5-chlorobenzamido)ethyl]benzyl}thiazolidine-2,4-dione.

Abstract: The compounds are substituted trimetazidine useful for the treatment of ischaemic pathologies and peripheral vascular pathology.A compound disclosed is 4-(2,3,4-trimethoxybenzyl)-1-[3-(4-hydroxy-2,3,5-trimethylphenoxy)propyl]p iperazine.

Abstract: The compounds are trisubstituted triazines and pyrimidines useful for the suppressing the resistance of tumour cells to anti-cancer agents and for suppressing the resistance of parasites to anti-parasitic agents.A compound disclosed is 2,4-diallylamino-6-{4-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl) methylamino]piperidin-1-yl}-1,3,5-triazine.

Abstract: The compounds are 2,4-(optionally substituted amino)-6-substituted s.triazines, useful for suppressing the resistance of tumour cells to anti-cancer agents and for suppressing the resistance of parasites to anti-parasitic agents.A compound disclosed is 1-[4,6-bis(allylamino)-2-s-triazinyl]-4-[2,2-bis(p.fluorophenyl)ethylamino ]piperidine.

Abstract: The invention relates to the use, for obtaining medicaments that reverse resistance to anti-cancer and anti-malarial agents, of compounds of formula I: ##STR1## in which A is --CH-- or nitrogen,and B, R.sub.1, R.sub.2 and R.sub.3 are as defined in the description,and their physiologically tolerable acid addition salts.

Abstract: The compounds are 8-substituted 1-oxa-2-oxo-3,8-diazaspiro [4.5]decanes useful for the treatment of dyslipidaemiae, atherosclerosis and pathologies in which membrane lipid peroxidation plays an initiating and/or aggravating role.A compound disclosed is (R,S)-8-[3(3,5-di-tert.-butyl-4-hydroxyphenylthio)-2-hydroxypropyl]-1-oxa- 2oxo-3,8-diazaspiro [4.5]decane.

Abstract: 1,3,7-trimethyl-8-[3-(4-diethylaminocarbonyl-piperazino) propyl] xanthine and physiologically tolerable acid addition salts thereof may be used for the preparation of medicaments for the treatment of memory disorders, intellectual disorders of ageing, and Alzheimer's disease.

Abstract: The compounds disclosed are 1-R'-4-RS-piperidines in which R' and R, which are different, may each represent: (1) (alkoxybenzyl)-alkyl or -alkenyl, or (2) (optionally-substituted chromanyl-, thiochromanyl-, chromenyl- or thiochromenyl)-alkyl or -alkenyl. The compounds are useful in the treatment of disorders associated with tissue ischaemia and of peripheral vascular disorders or in the treatment of disorders in which lipid peroxidation plays an initiating and/or aggravating role. A typical disclosed compound is: 4-(2,3,4-tirmethoxybenzylthio)-1-(3,5-di- tert-butyl-4-hydroxybenzyl)piperidine. ,3,4-trimethoxybenzylthio)-1-(3,5-di-tert-butyl-4-hydroxybenzyl)piperidine .

Abstract: New morpholine compounds of the formula: ##STR1## in which: X, bonded to the aromatic nucleus, represents halogen or trifluoromethyl and R' represents hydrogen, (C.sub.1 -C.sub.5)alkyl optionally including a double bond, or aralkyl; in racemic and enantiomeric forms, and physiologically tolerable acid addition salts theroef.These compounds and their physiologically tolerable salts can be used therapeutically especially in the treatment of ischaemic syndromes and cerebral ageing.

Abstract: New aminochromanol compounds of the formula: ##STR1## in which X is cyano, nitro, trifluoromethyl, alkoxycarbonyl, carbamido, dialkylcarbamido, aminosulfonyl, dialkylaminosulfonyl, alkylsulfonyl, alkylsulfonylamino or acyl;CH.sub.2 -R is attached (in the 5 position of the pyrrolidinone nucleus) to an R- or S-configured carbon atom, and R is:either OR' or SR' in which R' is hydrogen, (C.sub.1 -C.sub.10)-alkyl, (C.sub.1 -C.sub.5 -alkyl)-carbonyl or ##STR2## and physiologically tolerable acid addition salts thereof, in the case where R contains a basic function.These compounds and their physiologically tolerable salts can be used in therapeutics for the activation of potassium channels, especially in the treatment of disorders associated with abnormal smooth muscle contraction and in the cardiovascular, bronchopulmonary, digestive, urinary and uterine fields.

Abstract: New benzopyrrolidinone compounds, which can be used as medicaments and correspond to the formula ##STR1## in which: either: R.sub.1 and R.sub.2 together represent, with the bond of the etherocycle to which they are attached, an optionally substituted benzene nucleus and, simultaneously, R.sub.3 and R.sub.4 are hydrogen, (C.sub.1 -C.sub.4)alkyl or (C.sub.5 -C.sub.6)cycloalkyl;or:R.sub.1 is hydrogen, R.sub.4 is a single bond and R.sub.2 and R.sub.3 together represent, with the bond of the heterocycle to which they are bonded, an optionally substituted benzene nucleus; andA is a straight or branched hydrocarbon chain having from 2 to 6 carbon atoms that is optionally substituted by hydroxy;X is a single bond, oxygen or sulphur; andY is hydrogen, halogen or (C.sub.1 -C.sub.5)alkyl or alkoxy.These new compounds and the physiologically tolerable salts thereof can be used therapeutically, especially in the treatment of bronchospastic disorders and inflammations in the ENT area.

Abstract: Spiro (4,5) decane compounds of the formula: ##STR1## in which: X is methyl andY is hydrogen or R'--CO-- in which R' is C.sub.1 -C.sub.4 -alkyl or C.sub.1 -C.sub.4 -alkoxy, ##STR2## X and Y together represent ##STR3## in each of which A is hydrogen, methyl, carboxy, methoxycarbonyl or ethoxycarbonyl;R is C.sub.1 -C.sub.7 -alkyl optionally containing a double bond;Z is a C.sub.2 -C.sub.7 -polymethylene chain optionally carrying an OH group;R.sub.1 is hydrogen or methyl; andR.sub.2 is hydrogen, R'--CO-- or benzyloxycarbonyl;and physiologically tolerable acid addition salts thereof.These compounds may be used therapeutically especially in the treatment of asthma, allergic phenomena and bronchopathies.

Abstract: 5-aminopentanenitrile compounds of the formula: ##STR1## in which: Ar represents ##STR2## in which: R.sub.1 is hydrogen, halogen trifluoromethyl or C.sub.1 -C.sub.5 -alkoxy, andR.sub.2 and R.sub.3, which are identical or different, each are hydrogen or C.sub.1 -C.sub.5 -alkoxy or together form --O--CH.dbd.CH--O-- or --O--CH.sub.2 --O--; or together form with the phenyl ring to which they are bound a benzoxazolyl, benzothiazolyl, benzothiadiazolyl or quinolyl radical;R is C.sub.3 -C.sub.15 -alkyl or ##STR3## in which: X is S or SO.sub.2 and Z is hydrogen, chlorine or C.sub.1 -C.sub.5 -alkyl or C.sub.1 -C.sub.5 -alkoxy;R' is C.sub.1 -C.sub.5 -alkyl, andAr' represents ##STR4## in which: R'.sub.1 is C.sub.1 -C.sub.5 -alkyl andR'.sub.2 is hydrogen or C.sub.1 -C.sub.4 -alkyl; and moreover when R is ##STR5## Ar' may be ##STR6## in which Y is C.sub.1 -C.sub.5 alkoxy andY' is hydrogen or C.sub.1 -C.sub.

Abstract: Morpholine compounds of the formula: ##STR1## in which R.sub.1 is hydrogen, straight-chain or branched (C.sub.1 -C.sub.6)-alkyl which may contain a double bond, aralkyl which may be substituted, (C.sub.5 -C.sub.6)-cycloalkyl or (C.sub.2 -C.sub.6)-acyl; andR.sub.2 is hydrogen, straight-chain or branched (C.sub.1 -C.sub.6)-alkyl which may contain a double bond, aralkyl which may be substituted, or (C.sub.2 -C.sub.3)-acyl; enantiomers and physiologically tolerable acid salts thereof.These compounds may be used therapeutically especially in the treatment of ischaemic syndromes and of cerebral ageing.